Paolo Ghia

Research interests

Publications

• Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2300696

• The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

  Blood · 2022 · https://doi.org/10.1182/blood.2022015851

• Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

  Blood Advances · 2022 · https://doi.org/10.1182/bloodadvances.2021006434

• Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

  Blood · 2022 · https://doi.org/10.1182/blood.2021014488

• Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00293-5

• Genomic profiling for clinical decision making in lymphoid neoplasms

  Blood · 2022 · https://doi.org/10.1182/blood.2022015854

• Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

  Blood · 2021 · https://doi.org/10.1182/blood.2021011568

• Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00224-5

• Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.01210

• Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.00807

• ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.19.03355

• COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0959-x

• Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)30262-2

• Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.09.019

• Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact

  Blood · 2019 · https://doi.org/10.1182/blood-2018-09-873083

• Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

  Blood · 2019 · https://doi.org/10.1182/blood.2018884940

• Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

  Leukemia · 2019 · https://doi.org/10.1038/s41375-019-0602-x

• The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

  Blood · 2018 · https://doi.org/10.1182/blood-2018-05-850461

• ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

  Leukemia · 2018 · https://doi.org/10.1038/s41375-017-0007-7

• Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

  Cytometry Part B Clinical Cytometry · 2017 · https://doi.org/10.1002/cyto.b.21595

• Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1509981

• Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

  Blood · 2015 · https://doi.org/10.1182/blood-2015-06-651125

• Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1509388

• A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

  Leukemia · 2015 · https://doi.org/10.1038/leu.2015.313

• Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1315226

• Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

  Blood · 2012 · https://doi.org/10.1182/blood-2011-11-393694

• Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis

  Blood · 2007 · https://doi.org/10.1182/blood-2007-07-099564

• Diagnostic criteria for monoclonal B‐cell lymphocytosis

  British Journal of Haematology · 2005 · https://doi.org/10.1111/j.1365-2141.2005.05550.x

Current projects

No projects listed.